Diabetes & Obesity
Breakthrough treatments for diabetes and obesity aim to stem the rising epidemic of complications and deaths directly attributed to these conditions.
Diabetes and obesity are two interconnected health conditions that pose significant global challenges. Diabetes is a chronic metabolic disorder characterized by elevated blood sugar levels, resulting from either insufficient insulin production (Type 1 diabetes) or ineffective utilization of insulin (Type 2 diabetes). It leads to various complications affecting multiple organ systems. Obesity, on the other hand, refers to excessive body weight caused by numerous contributing factors, such as poor diet, sedentary lifestyle, genetics, hormonal imbalances, medications, and environmental influences. Obesity significantly increases the risk of developing Type 2 diabetes and exacerbates its complications and is also a significant risk factor in the development of cancer and MASH (metabolic dysfunction-associated steatohepatitis). When these conditions cannot be managed through diet and physical activity, therapeutic intervention may be required.
Unique Products to Advance Diabetes and Obesity Research
Our engineered tools for diabetes and obesity enable research applications, such as screening for potent receptor agonists.
Luciferase Reporter Cell Lines
- GLP-1R, GIPR, and GCGR-expressing reporter cell lines measure receptor activation by the production of firefly luciferase
- Thyroid Hormone Receptor β luciferase reporter cell line
- Ideal systems for high-throughput screening of receptor agonists or antagonists
- Optimized thaw and growth media available
- Use our ONE-Step™ Luciferase Assay System to quantitate luciferase activity
- Reduced cost Cell Line Rental Program available
Dose response of GIPR agonists in GIPR/CRE Luciferase Reporter HEK293 cells. Cells were incubated with increasing concentrations of GIP (left) and Trizepatide (right).
Luciferase Reporter Cell Lines
- GLP-1R, GIPR, and GCGR-expressing reporter cell lines measure receptor activation by the production of firefly luciferase
- Thyroid Hormone Receptor β luciferase reporter reporter cell line
- Ideal system for high-throughput screening of receptor agonists or antagonists
- Optimized thaw and growth media available
- Use our ONE-Step™ Luciferase Assay System to quantitate luciferase activity
- Reduced cost Cell Line Rental Program available
Dose response of GIPR agonists in GIPR/CRE Luciferase Reporter HEK293 cells. Cells were incubated with increasing concentrations of GIP (left) and Trizepatide (right).
Recombinant Proteins
- Includes: ACC1, ACC2, Insulin, Insulin Receptor, Insulin-Degrading Enzyme (IDE), Insulin-Like Growth Factor I (IGF-I), IGF1 Receptor, Insulin receptor-related receptor (IRR)
- Ideal for binding studies or activation/inhibitor studies
- Bulk discounting available
Custom Product Development
Can’t find the product you are looking for? Our experts could build it for you. Learn more.
Product Results
Inquiries
│Featured Products
- TRβ-GAL4 Luciferase Reporter HEK293 Cell Line (Thyroid Hormone Receptor β Pathway)
- GCGR/CRE Luciferase Reporter HEK293 Cell Line
- GIPR/CRE Luciferase Reporter HEK293 Cell Line
- GLP-1R/CRE Luciferase Reporter HEK293 Cell Line
- Insulin & Insulin Receptor Related Recombinant Proteins
- ACC1 Assay Kit
- ACC2 Assay Kit
- FXR Agonist Assay Kit (TR-FRET)